What makes a good SMC submission

Download Report

Transcript What makes a good SMC submission

What makes a good SMC
submission
Barbara McLaughlan,
Campaigns Manager RNIB
John Legg, Director RNIB Scotland
1
Background to the Submission
• Introduction of Lucentis, a drug for wet
Age-related Macular Degeneration
(AMD)
• AMD causes a progressive, irreversible
loss of central vision in older people
• Wet AMD is the most aggressive form of
this disease and has significant public
health implications
2
Homework
• Analyse medical and economic data
• Demonstrate patient experiences
with the drug under appraisal
• Provide comparison with alternative
treatments and best comparative
care
• Evidence all aspects of the
submission
• Seek expert involvement
3
Methodology
• Literature Review and Primary
Research
• Telephone interviews with patients
• Patient Case Studies
• Impact analysis
4
Patient-centred Focus
•
•
•
•
Effective use of case studies to
illustrate points and bring the
submission alive
Select case studies well and keep
them short to make clear points
Do not use them exclusively to make
your case
Individual experiences have to be
backed up by scientific evidence
5
Adopting the Right Approach
• Recognise your own expertise and
contribution
• Guard against bias
• Avoid being antagonistic
• Present the whole picture
6
Involve Allies
• If possible, join forces with other patient
organisations interested in having the
same drug approved. It can only
strengthen your voice
7
Putting it in Context
•
•
•
•
•
Sight loss
Patient impact
Economic impact
Health environment
SMC approval
8
Sight Loss
•
•
•
•
•
One in eight
One in three
Double by 2031
50 per cent plus of those registered
Increases risk
9
Patient Impact
• “I was devastated when I was told I had
Macular Degeneration”
• “I lost my job, my income, my identity as
a teacher, my driving license, my social
network, my house, my independence
and I had sunk into deep depression
whilst struggling to care for my family”
10
Economic Impact
•
•
•
•
•
Increased usage of health services
£237,000
4.9 billion
7.1 million
4 fold return
11
Scottish Vision Strategy
12
Health Environment
•
•
•
•
•
Government policy drivers
Public health priorities
Resource pressure
Competing demands
Implementation realities
13
SMC Approval
• Creates a treatable condition
• Meets World and Scottish policy
objectives
• Prevents thousands losing their sight
• Contributes to wider social concerns
14
SMC Refusal
•
•
•
•
•
Patient impact
Evidence check
Others shoes
Devils Advocate
Restructure and tighten
15
Thank You
• “My general roundabout vision has
improved”
• “It lets you continue life”
16